![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HIF3A |
Gene summary for HIF3A |
![]() |
Gene information | Species | Human | Gene symbol | HIF3A | Gene ID | 64344 |
Gene name | hypoxia inducible factor 3 subunit alpha | |
Gene Alias | HIF-3A | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q9Y2N7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64344 | HIF3A | ATC12 | Human | Thyroid | ATC | 9.50e-14 | 2.73e-01 | 0.34 |
64344 | HIF3A | ATC13 | Human | Thyroid | ATC | 4.54e-53 | 1.06e+00 | 0.34 |
64344 | HIF3A | ATC4 | Human | Thyroid | ATC | 8.26e-18 | 3.62e-01 | 0.34 |
64344 | HIF3A | ATC5 | Human | Thyroid | ATC | 4.84e-63 | 1.12e+00 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HIF3A | SNV | Missense_Mutation | rs751873472 | c.1195G>A | p.Glu399Lys | p.E399K | Q9Y2N7 | protein_coding | tolerated(0.17) | possibly_damaging(0.557) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF3A | SNV | Missense_Mutation | rs371476587 | c.499C>T | p.Arg167Cys | p.R167C | Q9Y2N7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF3A | SNV | Missense_Mutation | novel | c.1861N>A | p.Gly621Arg | p.G621R | Q9Y2N7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.005) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HIF3A | SNV | Missense_Mutation | novel | c.449N>T | p.Thr150Ile | p.T150I | Q9Y2N7 | protein_coding | deleterious(0.01) | benign(0.141) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
HIF3A | SNV | Missense_Mutation | novel | c.911A>G | p.Tyr304Cys | p.Y304C | Q9Y2N7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HIF3A | deletion | Frame_Shift_Del | c.1638delN | p.Arg548GlyfsTer2 | p.R548Gfs*2 | Q9Y2N7 | protein_coding | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |||
HIF3A | SNV | Missense_Mutation | c.1202N>A | p.Ala401Asp | p.A401D | Q9Y2N7 | protein_coding | tolerated(0.27) | benign(0.039) | TCGA-CC-A7II-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
HIF3A | SNV | Missense_Mutation | c.1652N>T | p.Cys551Phe | p.C551F | Q9Y2N7 | protein_coding | tolerated_low_confidence(0.07) | benign(0.003) | TCGA-DD-A11D-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
HIF3A | SNV | Missense_Mutation | novel | c.719C>A | p.Ala240Asp | p.A240D | Q9Y2N7 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-DD-AAW2-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
HIF3A | SNV | Missense_Mutation | rs562383855 | c.1552N>A | p.Ala518Thr | p.A518T | Q9Y2N7 | protein_coding | tolerated(0.26) | benign(0) | TCGA-G3-A3CJ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |